PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...
Vietnam Investment Review on MSN
CO PSMA prostate imaging data presented at EAU congress
SYDNEY, March 17, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...
A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...
A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.
Serial proteomic characterization of plasma extracellular vesicles (EV) to identify changes that predict outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA ...
Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...
Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.
The company will use Origin Wireless’ AI sensing to expand the capabilities of its smart home security products. The company will use Origin Wireless’ AI sensing to expand the capabilities of its ...
Tyler has worked on, lived with and tested all types of smart home and security technology for over a dozen years, explaining the latest features, privacy tricks, and top recommendations. With degrees ...
SBRT administered to oligometastases was associated with survival benefits in phase 2 trial participants with CRPC receiving abiraterone and ADT. For patients with oligometastatic castrate-resistant ...
Thank you for standing by, and welcome to the ADT Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions] I'd now like to turn the call over to Elizabeth Landers, Vice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results